The finaloverall survival results from the KEYNOTE-355 study showed a statistically significant 27% reduction in the risk of death for patients with metastatic triple-negative breast cancer whose tumors were strongly positive for PD-L1, defined as a combined positive scor...
Pembrolizumab plus chemotherapy in Japanese patients with triple-negative breast cancer: Results from KEYNOTE-355breast cancerPembrolizumab plus chemotherapy improved progression-free survival (PFS) and overall survival (OS) compared with placebo plus chemotherapy in patients with previously untreated locally ...
Superior overall survival with KEYTRUDA + plat/pem vs plat/pem alone Overall Survival (OS) KEYTRUDA + plat/pem (n=410)Plat/pem (n=206) HR=0.49 (95% CI, 0.38–0.64; P<0.0001)a Events Observed 127(31%) Events Observed 108(52%) Median OS Not reached(95% CI, NR–NR) Median OS 11...
“Using Microsoft AI, Providence researchers were able to find actionable biomarkers for a majority of patients and, consequently, many patients were prescribed with precision therapy, which substantially increased overall survival.” –Hoifung Poon, General Manager, Microsoft Health Futures Transcript:...
Overall Survival (OS)1,e KEYTRUDA 10 mg/kg IV Q3W (n=277)KEYTRUDA 10 mg/kg IV Q2W (n=279)Ipilimumab IV (n=278) HRf=0.68; 95% CI, 0.53–0.86;P=0.00083g HRf=0.68; 95% CI, 0.53–0.87;P=0.00085g — Median OS Not reached (NR) ...
Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2–positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Final overall survival (OS) results from a randomized, multicenter, open-label, phase ...
Cambridge University Hospitals NHS Foundation Trust in the United Kingdom, called the findings “practice-changing” and in line with “the large pantheon” of global phase III trials showing “very consistently” that immune checkpoint inhibition plus chemotherapy can ...
The overall survival (OS) data are not yet mature, so they weren’t presented. Patients in the chemotherapy arm did crossover to the pembrolizumab arm. More than half of the patients who received chemotherapy went on to receive pembrolizumab or another anti–PD-1 in the second-line set...
The expert panel reviews the KEYNOTE-775 trial, which focused on lenvatinib and pembrolizumab in advanced endometrial cancer.
Based on the recommendation of the DMC, the trial will continue without changes to evaluate the other dual primary endpoint of overall survival (OS). The safety profile of KEYTRUDA in this trial was consistent with that observed in previously reported studies; no new safety signals were identified...